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Since the airways of control mouse lungs contain few alcian blue/periodic acid–Schiff’s
(AB/PAS)+ staining ‘goblet’ cells in the absence of an inflammatory stimulus such as allergen
sensitization, it was surprising to find that the lungs of mice deficient for the exocytic priming
protein Munc13-2 stain prominently with AB/PAS under control conditions. Purinergic agonists
(ATP/UTP) stimulated release of accumulated mucins in the Munc13-2-deficient airways,
suggesting that the other airway isoform, Munc13-4, supports agonist-regulated secretion.
Notably, however, not all of the mucins in Munc13-2-deficient airways were secreted, suggesting
a strict Munc13-2 priming requirement for a population of secretory granules. AB/PAS+
staining of Munc13-2-deficient airways was not caused by an inflammatory, metaplastic-like
response: bronchial–alveolar lavage leucocyte numbers, Muc5ac and Muc5b mRNA levels, and
Clara cell ultrastructure (except for increased secretory granule numbers) were all normal. A
Muc5b-specific antibody indicated the presence of this mucin in Clara cells of wildtype (WT)
control mice, and increased amounts in Munc13-2-deficient mice. Munc13-2 therefore appears
to prime a regulated, baseline secretory pathway, such that Clara cell Muc5b, normally secreted
soon after synthesis, accumulates in the gene-deficient animals, making them stain AB/PAS+.
The defective priming phenotype is widespread, as goblet cells of several mucosal tissues appear
engorged and Clara cells accumulated Clara cell secretory protein (CCSP) in Munc13-2-deficient
mice. Additionally, because in the human airways, MUC5AC localizes to the surface epithelium
and MUC5B to submucosal glands, the finding that Muc5b is secreted by Clara cells under
control conditions may indicate that it is also secreted tonically from human bronchiolar Clara
cells.
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Oligomeric mucins secreted into the airways of healthy
lungs are important for normal mucociliary clearance,
and their hypersecretion contributes to pathophysiology
of the majority of airways diseases, chronic obstructive
pulmonary disease, asthma, cystic fibrosis, primary
ciliary dyskinesia, and the morbidity experienced by
the patients (see Rose & Voynow, 2006). Secretion of
mucins from airway goblet cells appears to be regulated
primarily by the agonists ATP and UTP, which activate
P2Y2 purinoceptors and phospholipase C to initiate
IP3/Ca
2+ and diacylglycerol (DAG)/PKC intracellular
signalling cascades (Davis, 1997; Kim et al. 2003; von
Kugelgen, 2006; Davis & Abdullah, 1997). Of the intra-
cellular events leading to exocytic mucin release (for
review, see Davis & Dickey, 2008), PKC and Ca2+
coordinate remodelling of the actin cytoskeleton to allow
interaction of mucin secretory granules with apical
membrane exocytic docking sites (Trifaro et al. 2002; Ehre
et al. 2005). Ca2+ also plays a major role in regulating
the final steps of exocytosis in goblet (Rossi et al. 2004,
2007) and other secretory cells (Klenchin & Martin, 2000;
Gerber & Sudhof, 2002; Bai & Chapman, 2004; Sudhof,
2004), by interacting with a host of C2-domain-containing
proteins, including rabphilin, Munc13 and synaptotagmin
(see Cho & Stahelin, 2006). DAG, however, also plays
an important role in regulating exocytic proteins by
attracting and activating those possessing C1 domains,
predominantly Munc13 and diacylglycerol kinase (see
Colon-Gonzalez & Kazanietz, 2006). In this study we
used Munc13-2-deficient mice to test whether this
isoform mediates agonist-regulated mucin secretion in
the airways. It was motivated by the findings that high
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doses of the DAG mimic, phorbol myristic acid, elicit
mucin secretion independent of PKC (Abdullah et al. 1997,
2003; Rossi et al. 2004), and that Munc13-2 and -4 are
expressed in airways (Koch et al. 2000; Abdullah et al.
2003). The results obtained, however, were unexpected
on three significant counts: the hypothesized function of
Munc13 in regulated exocytosis, that Clara cells appear to
secrete oligomeric mucins under control conditions in the
wildtype (WT) mouse airways, and that Muc5b appears to
be the major mucin expressed in the superficial epithelium.
Munc13 is a family of four isoforms (Fig. 1; see Koch
et al. 2000; Stevens et al. 2005; Basu et al. 2005), of
which, at least in rodents, Munc13-2 is expressed as two
splice variants. The brain variant, bMunc13-2, is similar
to Munc13-3 in lacking the C2A domain, whereas the
variant expressed ‘ubiquitously’, ubMunc13-2, is similar
to Munc13-1 in possessing a C2A domain. ubMunc13-2
is expressed in SPOC1 cells, a mucin-secreting cell line
derived from rat trachea (Abdullah et al. 2003). Munc13-1,
-2 and -3 couple individually with the small GTPases,
RIM and Rab3 in a tripartite complex (Betz et al. 2001;
Dulubova et al. 2005; Andrews-Zwilling et al. 2006) that
is required for exocytic priming of neuronal synaptic
vesicles and endocrine secretory granules (Martin, 2002;
Varoqueaux et al. 2002). Munc13-4 is a novel isoform
lacking both the C2A and the DAG-binding C1 domain
of the other Munc13 proteins, and is expressed widely
in the body, especially in lung and SPOC1 cells (Koch
et al. 2000; Abdullah et al. 2003). Munc13-4 is a Rab27
effector protein known to participate in the regulation of
melanosome transport and secretory lysosome secretion
(Zhang & Ginsburg, 2003; Neeft et al. 2005; Fukuda,
2005). It is also thought to be broadly active in regulating
exocytosis in many endocrine and exocrine secretory cells
(Fukuda, 2005; Bossi & Griffiths, 2005). How the isoforms
of these two Munc13 subfamilies function coordinately in
any individual secretory cell is unknown.
Despite its popularity as a model for allergic mucous
metaplasia relevant to asthma and other inflammatory
diseases of the lung where mucous metaplasia is
prominent, the mouse is unlike larger mammals, including
the rat (Kaartinen et al. 1993), in possessing very few
identifiable goblet cells in the airway under control
conditions. Indeed, a common finding is that alcian blue/
periodic acid–Schiff’s (AB/PAS)-stained sections of mouse
lung exhibit few to no visibly stained goblet cells (e.g.
see Cressman et al. 1998), unless metaplasia is induced
by allergic challenge, infection, etc. (see Evans et al.
2004; Williams et al. 2006). AB/PAS is a common
carbohydrate stain, which in the lung reveals mucin-
secreting cells by virtue of mucins being very rich
in glycans, ∼90% by weight. The gel-forming mucins
are linear, disulphide-linked oligomers with molecular
weights in the tens of mega-daltans that function as the
molecular scaffolding of mucus (see Thornton & Sheehan,
2004; Rose & Voynow, 2006). The predominant species
in the lung are Muc5ac and Muc5b, which in larger
mammals are thought to be secreted from goblet cells in
the superficial epithelium and from submucosal glands,
respectively (Groneberg et al. 2002). In the mouse airways,
submucosal glands are restricted to the cranial-most part
of the trachea and the primary secretory cell in the
superficial epithelium is the Clara cell, which expresses
high levels of cytochrome P450 and secretes Clara cell
secretory protein (CCSP, which is the same as CC10,
uteroglobin), a lipoprotein of poorly understood function
(Stripp et al. 2000). Under inflammatory conditions,
Clara cells undergo a metaplastic transformation by
up-regulating mucin synthesis and becoming AB/PAS+
(Evans et al. 2004; Williams et al. 2006). Hence, the
mouse lung presents a non-trivial conundrum in being
a commonly used model in biomedical research, one
that appears to possess a functional mucociliary clearance
system under control conditions (Kurosawa et al. 1995;
Cressman et al. 1998; Foster et al. 2001; Grubb et al. 2004),
but possesses no obvious source of mucins. Our surprise
finding of AB/PAS+ cells during histological examination
of the airways from mice deficient for Munc13-2 resolves
this conundrum and provides insight into the cellular




ATPγ S was purchased from Roche Applied Science
(Indianapolis, IN, USA); unless noted, all other
chemicals were purchased from Sigma Chemical Co.
(St Louis, MO, USA). A goat polyclonal anti-
body to CCSP was purchased from Santa Cruz
Biotechnology (S-20). A mouse Muc5b-specific, rabbit
polyclonal antibody was raised against a keyhole
limit himocyanin-conjugated synthetic peptide with the
sequence, CQPQCQWTKWIDVDY, which is repeated
5 times in the molecule in the Cys-rich domains that
precede the PTS domains. Pre-immune rabbit serum,
tested on agarose Western blots of mouse whole lung
extract and in immunohistochemistry (IHC), were
uniformly negative.
Mouse care and experimental procedures
Munc13-2+/− C57/B6 mice were kindly provided by
Dr Niels Brose, Department of Molecular Neuro-
biology, Max-Planck-Institute of Experimental Medicine,
Germany. All animals were bred and raised at the
University of North Carolina, and were allowed food
and water ad libitum. Some animals were treated
with an ovalbumin tracheal instillation under isoflurane
anaesthesia as described below; all animals were ultimately
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killed with gaseous CO2 prior to tissue harvest by
dissection. All experimental procedures using mice were
conducted under protocols approved by the University
of North Carolina Institutional Animal Use and Care
Committee.
Airway mucus metaplasia
Airway mucus metaplasia was induced in mice through
ovalbumin (OVA) sensitization and challenge (see Cohn
et al. 2002; Evans et al. 2004) using a procedure detailed
previously (Ehre et al. 2007). Briefly, OVA was injected
i.p. into each mouse on days 0, 7 and 14, and on days
21 and 24, 50 μl of 2.0% OVA in PBS was instilled by
aspiration into tracheas of isoflurane-anaesthetized mice.
The instillation procedure was completed in < 20 s, well
within the ∼1 min period of time it takes the mouse to
recover from the isoflurane anaesthesia; recovery from
the procedure was 100%. Experimental procedures were
performed 3–14 days following the 2nd OVA instillation.
Broncho-alveolar lavage
Broncho-alveolar lavage (BAL) was used to analyse
inflammatory cells. Mice were killed with CO2 and the
trachea, exposed through a neck incision, was severed
and cannulated with a blunt 20G needle. The chest
cavity was opened and 3-0 silk suture was used to
tie off the left lung lobe, to restrict the BAL to the
right lobe. Phosphate-buffered saline (PBS), 17.5 μl
(g body weight)−1 and containing Complete Mini Protease
Inhibitor protease inhibitor cocktail (1 tablet in 10 ml;
Roche, Penzberg, Germany), was slowly injected into
the lobe and recovered a total of 3 times, the procedure
was repeated once, the two collections were pooled,
centrifuged (600 g , 5 min, 4◦C), and the pellet resuspended
in 100 μl PBS. Total cell number was determined using
a haemocytometer, and cell composition by identifying
and counting > 200 cells per sample stained with
Wright-Giemsa, on air-dried samples prepared by cytospin
analysis (StatSpin Cytofuge, Iris International, Westwood,
MA, USA).
Naphthalene injury
Naphthalene injury was used to test whether mucins
were expressed in Clara cells (Plopper et al. 1992; Van
Winkle et al. 1995; Rawlins et al. 2007). Adult mice
(8–14 weeks) were injected, between 08:00 and 10:00 h,
peritoneally, with 250 mg kg−1 naphthalene dissolved in
fresh (< 1 month old) Mazola corn oil; control mice
received vehicle only. Two days later, the mice were killed
and lung tissue harvested for histological analysis.
Tracheal perfusion, mucin ELISA
Tracheas were harvested from mice killed with CO2,
cannulated at the proximal end, and perfused at
50 μl min−1 with warmed, 5% CO2–95% O2-equilibrated
DMEM/F12 as detailed previously (Ehre et al. 2007). A
pair of preparations were mounted on a custom bracket
attached to the arm of a Gilson FC204 microtitre plate
fraction collector (Middleton, WI, USA) such that the
effluent dripped from the open ends of the tracheas
directly into the wells of 96-well, non-binding, polystyrene
microtitre storage plates (Corning, no. 3594), with
collections timed at 5 min. The entire set-up (pump,
solutions, tissues, fraction collector) was housed in
a humidified Nuaire DH Autoflow CO2 incubator
(Plymouth, MN, USA), factory customized to lie
horizontally.
Mucins in the collected fractions were assessed by an
ELISA (Ehre et al. 2007), using a mucin ‘subunit antibody’
that recognizes all vertebrate oligomeric mucins (Sheehan
et al. 1991). Standard curves were generated from purified
SPOC1 mucins (Abdullah et al. 1996) applied to each
plate, and the results were expressed as the equivalent
nanogram of mucin released per each fraction for each
trachea. Apparent differences between sample means in
these experiments were subjected to a Student’s t test,
assuming equal variances, with statistical significance
being indicated at P < 0.05.
Histology, immunohistochemistry and confocal
microscopy
Tissues fixed in formalin were dehydrated and embedded
in paraffin, sections cut at 5 μm were placed on slides,
deparaffinized and rehydrated. AB/PAS staining followed
standard protocols, using a 5 min incubation in 0.5%
periodic acid. Sections for IHC using immunofluorescent
probes were first treated for antigen retrieval using HIER
solution (SI 700, Dako, Carpinteria, CA, USA) for 30 min,
at 98.8◦C, before being circled with a liquid repellent pen
and placed into a humidified container. The sections were
then treated with Image-it FX (Molecular Probes, Eugene,
OR, USA) to reduce autofluorescence, and blocked (0.05%
saponin, 1% BSA in PBS) for 2 h at room temperature,
following which they were incubated with the primary
antibody, diluted in blocking solution. They were then
incubated overnight at 4◦C, then in the appropriate
fluorescently conjugated secondary antibody, in blocking
solution, for 1 h at room temperature. The sections
were washed and coverslips applied with Prolong Gold
mounting media (Molecular Probes). For the experiment
shown in Fig. 6B, a peroxidase conjugated goat anti-rabbit
antibody (1 : 200; Vectorlabs, Burlington, VT, USA) and
diaminobenzidine (DAB; Vectorlabs) was used. For each
experiment, the immunostaining procedure was repeated
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a minimum of 3 times, and the possibility of non-specific
binding was ruled out by staining sections with rabbit or
goat IgG.
Immunofluorescence was visualized using a Zeiss 510
Meta (Carl Zeiss International, Oberkochen, Germany)
laser scanning confocal microscope. The secondary anti-
bodies were excited with 488 nm argon and 543 nm
He–Ne1 lasers. Differential interference microscopy (DIC)
was used, simultaneously, to visualize the tissue for general
morphology. Photomultiplier gains and offsets for the
two fluorescence channels were adjusted at each viewing
session to minimize cross-talk. Zeiss 510 imaging software
was used for image analysis. The images and protein
distributions presented in Results are fully representative
of all images examined.
Electron microscopy
Aldehyde-fixed mouse lung tissue was washed in 0.1 m
Sorenson’s buffer for 1 h at 4◦C (×3), post fixed in 1%
OsO4 in 0.1 m Sorenson’s buffer for 1 h at 4
◦C, and rinsed
in filtered distilled water for 5 min. The tissues were
dehydrated in graded ethanol at room temperature for
10 min, immersed in propylene oxide for 20 min (×2),
then infiltrated with a 1 : 1 mixture of propylene oxide and
pure epon resin overnight at room temperature, and then
in pure resin for 4 h. Sections 90 nm thick, cut onto copper
grids and stained with uranyl acetate and lead citrate,
were viewed with a Zeiss EM900 transmission electron
microscope.
RT-PCR
Mouse tissues destined for mRNA analysis were cut into
small pieces and immersed in RNAlater reagent (Sigma),
then stored at −80◦C until use. Total RNA was extracted
by thawing tissue into RLT buffer (Qiagen, Valencia,
CA, USA) and homogenizing with a Fisher PowerGen
125 homogenizer. For selective isolation of RNA from
tracheal epithelium, tracheal lumens were exposed directly
to RLT buffer for 15 min, then harvested, following which
the residual tracheal tissue was extracted, with homo-
genization, in RLT buffer. Total RNA was purified from
extracts using an RNeasy Mini Kit (Qiagen) and quantified
using a NanoDrop spectrophotometer (Wilmington, DE,
USA).
Conventional RT-PCT was used to identify Munc13
isoforms. SuperScript II (Invitrogen, Carlsbad, CA,
USA) was used to reverse transcribe 500 ng total RNA,
using oligo(dT) 15-mer primers, following which 50 ng
cDNA was amplified by PCR using GoTaq Green Master
Mix (Promega, Madison, WI, USA) and forward and





and Munc13-4 (AGGGAAGCCCTTCATCCTGT, TCT-
GTAGACAGCCAAACTCC).
Quantitative, real time PCR (qRT-PCR) was used
to analyse mucin and CCSP mRNAs in mouse
lung extracts on 20 ng of random-primed, reverse
transcribed cDNA using a LightCycler (Roche), and
forward and reverse primers, respectively, as follows:
Muc5ac (CCATGCAGAGTCCTCAGAACAA, TTACTG-
GAAAGGCCCAAGCA); Muc5b (CTGGCCTCTGTA-
ACTATGT, CATAGCCACTGCTCTTCT); CCSP (AGC-
CTCCAACCTCTACCA, AGGGATGCCACATAACCA).
For each gene, a standard curve was used to calculate the
efficiency of the PCR reaction, and the data were analysed
and expressed relative to WT controls using the method
of Pfaffl (Pfaffl, 2001).
Collection and analysis of Muc5b glycoprotein
Mucins were solubilized from whole lung tissue using
a guanidinium chloride (GuCl) extraction buffer (6 m
GuCl, 100 mm Tris-HCl, 5 mm EDTA, pH 8.0, with
1 tablet protease inhibitor per 7 ml working buffer, see
BAL section above), either by immersing the left lung lobe
in 1 ml of extractant, or by injecting 0.6 ml into the whole
lung via the trachea, following which it was immersed in
1 ml of extractant. In both cases, the tissue was chopped
into small pieces with scissors, stirred overnight at 4◦C,
centrifuged (16 000 g , 30 min, 4◦C), and the supernatant
dialysed overnight at 4◦C against 6 m urea buffer (6 m
urea, 100 mm Tris-HCl, 5 mm EDTA, pH 8.0) and stored at
−80◦C until use. Protein concentrations were determined
using a BCA assay (Pierce, Rockford, IL, USA). Mucins
were analysed by agarose Western blotting, as detailed
previously (Kirkham et al. 2002; Holmen et al. 2004).
Briefly, mucins in whole lung extract, ≤ 40 μl, were
resolved by electrophoresis in 1% agarose gels (80 V,
2 h), and transferred by vacuum blotting (VacuGene XL,
GE Heathcare, Piscataway, NJ, USA) to nitrocellulose
membranes. Blots were probed with Muc5b antibody and
developed with enhanced chemiluminescence (Pierce).
Results
Munc13-4 is expressed in lung (Koch et al. 2000) and with
ubMunc13-2 in SPOC1 cells (Abdullah et al. 2003), but it
was important to establish a more complete distribution of
Munc13 isoforms expressed in mouse airway epithelium
because their expression outside the brain is poorly known
(e.g. see Augustin et al. 1999a). Figure 1 shows that only
Munc13-2 and -4 mRNAs were identified in tracheal
epithelium (selective, luminal exposure to the extraction
buffer) and nasopharynx, similar to the expression pattern
described for SPOC1 cells (Abdullah et al. 2003).
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Figure 1. Munc13 domain maps and mRNA expression in mouse tissues
Left, domain maps representing Munc13. The N-terminal splice variants for Munc13-2 are indicated in green
(b, brain) and blue (ub, ubiquitous). Note the lack of an N-terminal C2A domain in some genes, including the
brain splice-variant of Munc13-2. MUN, Munc13 homology domain. Right, conventional RT-PCR was used to
identify the Munc13 isoforms expressed in tracheal epithelium (luminal extraction), the residual tracheal tissue,
and nasopharynx. Thymus, thyroid and cerebellum were used as a source of positive control RNA for all Munc13
isoforms, and cerebrum (inset, upper right), additionally, was used for Munc13-1.
Effects of Munc13-2 deficiency on regulated mucin
secretion from control airways
Histological analysis of the airways from WT control
mice (Fig. 2A) confirmed the common observation that
cells staining with AB/PAS in the healthy epithelium
Figure 2. Mucin stores and secretion from control, non-OVA sensitized Munc13-2-deficient mouse air-
ways
A and B. AB/PAS-stained lung sections before (A) and after (B) tracheal perfusion and agonist challenge (T, trachea;
B, bronchus; scale bars in A = 30 μm, in B = 10 μm) C, tracheal mucin secretion, time course (left) and integrated
response (right). Isolated, perfused trachea were challenged with purinergic agonist (ATPγ S, 100 μM) during the
period indicated by the bar. Perfusates were collected at 5 min intervals and sampled for contained mucins by
ELISA. Data (mean ± S.E.M., n = 4) are normalized to the mean baseline period (30 min) preceding the agonist
challenge. Integrated response (right). Supra-baseline agonist-stimulated data for WT and Munc13-2-deficient
mice were summed, after subtracting the mean baseline, to estimate the integrated mucin secretory response;
∗P < 0.05.
are rare, particularly for C57B/6 mice (see Cressman
et al. 1998). In contrast, both the tracheal and bronchial
epithelia of Munc13-2-deficient mice contained significant
quantities of AB/PAS+ material, presumably mucins
(see below). Whether this accumulation of AB/PAS+
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material reflects the loss of a Munc13-2-mediated secretory
function directly, however, or is the indirect result of
a metaplastic-like response in the null mice is not
clear from the result. As a first step in answering this
question, we tested whether the accumulated mucins in
the Munc13-2-deficient mice could be secreted following
stimulation by purinergic agonists, which are well known
mucin secretagogues in the airways (Davis & Dickey,
2008). Using tracheal isolation and perfusion, and mucin
detection protocols established recently (Ehre et al. 2007),
tracheas from WT and Munc13-2-deficient mice were
challenged with the purinergic agonist ATPγ S. As shown
in Fig. 2C, perfused tracheas from Munc13-2-deficient
mice mounted a healthy secretory response to ATPγ S.
Analysis of the tracheas following agonist exposure,
however, showed that a substantial amount of AB/PAS+
material was retained following the 80 min challenge
(Fig. 2B). Agonist-exposed tracheas from the control,
WT mice released no detectible mucins above baseline
(Fig. 2C), as expected from the general lack of AB/PAS+
material in WT control airways (Fig. 2A). The WT baseline
data appear to diminish following agonist exposure, but
whether or not this change represents a significant decline
is unclear since the baseline secretion rates in these mice
are so low.
In summary, mucins accumulate in Munc13-2-deficient
mouse airways, possibly reflecting a functional deficiency
in a tonically active, baseline mucin secretion pathway.
Importantly, given the participation of Munc13-2 in
priming the SNARE complex of regulated exocytosis,
this pathway, by definition, would be a regulated,
Ca2+-dependent secretory pathway, not a constitutive
Figure 3. Mucin stores and secretion from OVA-sensitized, metaplastic mouse airways
A and B, AB/PAS-stained lung sections before (A; bronchus) and after (B; trachea) tracheal perfusion and agonist
challenge (scale bars in A = 30 μm, in B = 10 μm). C, tracheal mucin secretion, time course (left), integrated
response (right). Experiment per Fig. 2C (n = 5).
secretory pathway (Miller & Moore, 1991; Arvan & Castle,
1998; Ponnambalam & Baldwin, 2003; Gorr et al. 2005).
These results also show that a substantial portion of the
accumulated mucins can be released in response to agonist
stimulation, presumably under the control of Munc13-4
or other protein(s).
Effects of Munc13-2 deficiency on regulated mucin
secretion from metaplastic airways
To test whether Munc13-2 participates as a central
regulator of the mucin granule exocytic complex during
agonist-induced secretion, it was necessary to have
AB/PAS+ WT airways as proper controls, which was
achieved by inducing allergic mucous metaplasia with
OVA treatment of both WT and Munc13-2-deficient
mice. Lungs from such mice, sectioned and stained with
AB/PAS, indicated that the airways of both WT and
null mice were highly metaplastic, staining strongly with
AB/PAS (compare Fig. 3A with 2A). As shown in Fig. 3C,
tracheas from both the WT and Munc13-2-deficient mice
mounted robust mucin secretory responses in response to
agonist; however, the peak and integrated responses of the
Munc13-2-deficient tracheas appeared, unexpectedly, to
be greater than the WT controls. The difference between
the two groups of mice, though, was not significant
(P > 0.05). This result indicates, again, that Munc13-2 is
apparently not essential for agonist-induced secretion.
Interestingly, examination of tracheal epithelia
following the 80 min agonist exposure revealed significant
residual mucin stores (AB/PAS+ staining) in the
Munc13-2-deficient tracheas, whereas the WT control
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tracheas were completely depleted (Fig. 3B). Since
residual mucins were apparent after agonist exposure
only in tracheas of Munc13-2-deficient mice, whereas
the amounts of mucin in WT and Munc13-2-deficient
tracheas of OVA-sensitized mice were nominally similar
(Fig. 3, and see oligomeric mucin expression, below),
this isoform, again, appears to contribute in some
way to the regulation of mucin secretion even though
agonist-stimulated secretion can occur in its absence.
Does AB/PAS+ airways in Munc13-2 deficient mice
signify mucous metaplasia?
As noted above, the appearance of AB/PAS+ staining in
the airways of Munc13-2-deficient mice could be caused
by an inflammation-like response leading to mucous
Figure 4. Airway epithelium of Munc13-2-deficient mice is not metaplastic
WT and Munc13-2-deficient mice, without and with OVA treatment as indicated, were assessed for indications of
mucous metaplasia. A, BALF inflammatory cell profile. Mouse BAL fluids were assessed for total cells (inset) and
for relative cell composition (bar codes in inset). Data presented as the mean + S.E.M. (n = 4–6). Note the effects
of OVA treatment, but not of Munc13-2 genetic status. B, mucin gene expression in mouse lung. Whole lung
extracts were assessed for relative Muc5AC and Muc5B mRNA expression levels by qRT-PCR. Data are normalized
to the WT, control (OVA–) mice, and presented as the mean + S.E.M. (n = 3). C, electron micrographs of bronchial
Clara cell apical pole region. G, secretory granule; M, mitochondria; rER, rough ER; scale, 0.5 μm. Micrographs
shown are representative of those examined from 3 different mice for each condition.
metaplasia, such as is known to occur in transgenic
mice overexpressing the β subunit of the epithelial
Na+ channel (βENaC; Mall et al. 2004). We addressed
this possibility in three ways. First, bronchial–alveolar
lavage fluids (BALF) were harvested and the cells
quantified by cell type. As shown in Fig. 4A, there
were no differences in BALF total cells (inset), or
in the percentage composition of different cell types
between the non-OVA-treated mice, whether they were
WT or Munc13-2-deficient mice. OVA treatment, in
contrast, caused the appearance of inflammatory cells,
predominately eosinophils, to infiltrate the lung. Notably,
OVA had the same effects on the BALF cytologies
of the WT and Munc13-2-deficient mice. Additionally,
examination of haematoxylin and eosin stained sections
of non-metaplastic, WT and Munc13-2-deficient mice
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exhibited no evidence of inflammatory cell infiltrates in the
airways (data not shown). Both sets of data suggest the lack
of an inflammatory response in the Munc13-2-deficient
mice.
Second, we tested whether mucin gene expression was
up-regulated, as would be expected for an inflammatory
or inflammatory-like condition (Evans et al. 2004). Total
RNAs, extracted and purified from whole lungs of WT
and Munc13-2-deficient mice, and of WT OVA-treated
mice, were probed for Muc5ac and Muc5b mRNA levels by
qRT-PCR. When expressed against the WT controls, there
were no differences in mRNA levels for either mucin in
Munc13-2-deficient mice; however, Muc5ac and 5b levels
were increased in the OVA-treated WT mice, as expected
(Fig. 4B). Indeed, our data are consistent in this regard
with the recent findings of Young et al. in that Muc5ac
was up regulated in allergen-induced mucous metaplasia
by a much larger degree than was Muc5b. Additionally,
normalizing the data to 18S rRNA, the levels of Muc5b
in WT, control mice are estimated to exceed Muc5ac by
89-fold (data not shown), again in general agreement with
published data (Young et al. 2007).
Third, we examined airway Clara cells by electron
microscopy. There were greater numbers of secretory
granules in the apical pole regions of Munc13-2-deficient,
non-metaplastic Clara cells (Fig. 4C); otherwise, there
were no notable differences from WT. In contrast,
the metaplastic, WT Clara cells in OVA-treated mice
showed major changes in appearance, in addition to
increased numbers of granules. Chief among these were
the presence of dense-core granules, a more electron
dense cytoplasm, and the appearance of abundant rough
endoplasmic reticulum, a sign of increased secretory
protein synthetic activity. That these changes were not
observed in non-metaplastic Munc13-2-deficient Clara
cells is consistent with a mucin content that is increased
by decreased secretory activity, rather than increased
synthesis.
Oligomeric mucin expression in mouse lung
If Clara cells in the airways of Munc13-2-deficient mice
become AB/PAS+because oligomeric mucins are retained,
rather than secreted, then it should be possible to detect
mucins in WT control animals. Additionally, the mucin
content of the MUNC13-2-deficient mice should be
increased. To test these predictions, we determined the
relative amounts of Muc5b glycoprotein in whole lung
extracts of WT and Munc13-2-deficient mice by agarose
Western blotting. A significant effort was also made
to estimate Muc5ac glycoprotein levels, but neither the
specific antibodies we made nor any of the commercially
available antibodies yielded satisfactory results – both
gastric (control) mucins stained poorly, as did airway
mucins, even those extracted from lungs of OVA-treated
mice in which Muc5ac mRNA levels are up-regulated
(Evans et al. 2004). For Muc5b, the lungs were initially
extracted by immersion in 6 m GuCl buffer, the samples
reduced with DTT, and the relative staining intensities of
mucin bands in the blots determined. These data showed
consistently that there was more Muc5b in the lungs
of Munc13-2-deficient, than WT mice, especially in the
non-metaplastic lungs (n = 5 each; data not shown).
Muc5b agarose Western blots were next prepared
from unreduced and DTT-reduced samples, to resolve
high molecular weight Muc5b oligomers and mono-
mers, respectively. Material extracted by immersion in
GuCl buffer (Fig. 5, ‘Immersion Extraction’) from lungs
of OVA-sensitized animals showed clearly that Muc5b
in the unreduced (U) samples resolved as a structured
ladder of bands with increasing mobility, most likely
representing successively smaller mucin oligomers (see
Sheehan et al. 2004). When the samples were reduced
(R), this material resolved predominately as a single
band that had the same relative mobility as the positive
control, DTT-reduced material from submucosal glands
(Fig. 5, arrow), extracted from the tissue between the
cricoid cartilage and second tracheal ring. Hence, this
band probably represents mature, i.e. fully glycosylated,
Muc5b monomers. The Muc5b staining intensities of the
unreduced and reduced samples from the OVA-treated
Munc13-2-deficient mouse were more intense than those
from WT, but only slightly so.
DTT-reduced material extracted by immersion from
non-OVA-treated airways also stained positively for mono-
meric Muc5b, but as expected the staining intensities were
uniformly lower than OVA-treated material. In fact, there
was little or no apparent oligomeric Muc5b in the samples
from both the WT and Munc13-2-deficient mice, and
in the WT mice only the reduced sample exhibited any
staining at all. In these non-OVA-treated mice, however,
there were large differences between reduced samples from
WT and Munc13-2-deficient mice, consistent with the
notion of accumulated mucins in the deficient animals.
To increase the efficiency of mucin extraction, a
modified procedure was used for non-OVA-treated mice.
Before immersing the harvested lungs in GuCl buffer,
as above, a smaller volume of buffer was injected into
the airways through the carina. Hence, the lungs were
extracted from the airway epithelium outwards, insuring
good solubilization of the mucins in the airway epithelium.
As shown in the blot labelled ‘Luminal Extraction’ (Fig. 5),
this procedure yielded sufficient Muc5b to visualize mucin
oligomeric bands in agarose Western blots, especially for
the lungs from Munc13-2-deficient mice. In this case, a
well formed oligomeric ladder is apparent, whose bands
correlate reasonably well with those for the metaplastic
samples in the ‘Immersion Extraction’ blot. Muc5b
oligomers in the WT unreduced sample resolved as
very faint bands; however, the reduced sample yielded
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a heavily stained monomeric band indicating the clear
presence of Muc5b in lungs of the WT, control mouse.
Notably, there was a very large increase in Muc5b in
the lungs of Munc13-2-deficient mice, relative to WT.
Since there was not a commensurate increase in Muc5b
gene expression between these mice, the airways of the
Munc13-2-deficient mouse probably accumulate mucins
that would be normally secreted under baseline conditions.
Luminal extraction of the mucins produced clear bands
of higher mobility in the agarose Western blots (Fig. 5, left,
asterisks), that probably represent the non-glycosylated
Muc5b dimer (non-reduced) and monomer (reduced)
units. Faint bands at these positions can also be identified
in the mucins resolved from OVA-treated airways. Also
interesting is the apparent increase in Muc5b staining
intensity that occurs when the mucins are reduced,
particularly in mucins from the WT control mice. Part
of the explanation may lie with the material observed
in the prominent reduced band, being dispersed over
numerous, less mobile bands in the non-reduced material.
An additional possibility, however, is that some, or even
most, of the five repeats of the antibody target sequence
in the non-reduced, oligomeric form of Muc5b (see
Experimental procedures) may be hidden from the anti-
body inside the tertiary structure of the glycoprotein, and
exposed following reduction.
Mucin and CCSP expression in Clara cells
Clara cells being the only secretory cell in WT, control
mouse airways makes them the likely source of mucins.
Figure 5. Muc5b glycoprotein expression in mouse lung
The presence of Muc5b was assessed in whole lung extracts by agarose Western blotting. The arrow, left, indicates
the Muc5b glycosylated monomer band in submucosal gland extract (S. Gland), which served as a positive control.
‘Immersion extraction’ (left-hand blots) is lungs immersed in GuCl buffer. ‘Luminal Extraction’ (right-hand blot)
is GuCl buffer injected into airways prior to immersion in GuCl buffer. U, unreduced; R, reduced (DTT). Samples
from non-OVA-sensitized and OVA-sensitized animals are indicated at the bottom. The bands at positions in the
right-most blot indicated by ∗ are interpreted as the non-glycosylated, Muc5b dimer (unreduced) and monomer
(reduced), precursors of the mature mucin. Blots are representative of 3 or more prepared for each condition.
This notion was tested in two ways. First, Muc5b and CCSP
were localized in the airway epithelium by IHC. Figure 6A
shows that Muc5b co-localized with CCSP in Clara cells
under all conditions, i.e. in WT cells, both without and with
OVA treatment, and in Munc13-2-deficient cells. With
the FITC conjugated secondary antibody used in these
experiments, however, Muc5b did not appear to stain all
CCSP-staining cells, especially in the WT control tissue.
Importantly, cells that did stain positively for Muc5b were
also CCSP positive.
To better assess the distribution of Muc5b glycoprotein
expression in WT control mice, we used a more sensitive
IHC technique, namely a HRP-conjugated secondary anti-
body. As Fig. 6B illustrates, this technique showed Muc5b
to be distributed widely in the airways, from the axial
bronchus, where it is most heavily expressed, down to the
small airways. It does not appear, however, to be expressed
in the terminal bronchioles (Fig. 6Bc).
As a second test of mucin expression in Clara cells,
naphthalene was used to injure the epithelium, using
a protocol developed to direct the injury selectively to
Clara cells, which express high levels of P450 (Hong et al.
2001; Rawlins et al. 2007). Trachea and lung sections
were stained with AB/PAS 2 days following treatment. As
shown in Fig. 7, treating WT OVA sensitized (control)
mice and Munc13-2-deficient non-OVA sensitized mice
with naphthalene resulted in a loss of AB/PAS+ staining,
suggesting that mucins are expressed in Clara cells.
The overall reduction in epithelial height seen in the
naphthalene-treated tissues reflects the fact that Clara cells
are a major cell type in mouse airways. The selective loss
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Figure 6. Mucin and CCSP expression in mouse
airways
A, Muc5B and CCSP co-localization. Sections of
bronchial epithelium from WT and Munc13-
2-deficient mice, without or with OVA sensitization
as indicated, were stained for Muc5B (green) and
CCSP (red), and examined by confocal microscopy.
The images shown, representative of sections from 3
mice each, are overlays of green, red and DIC
images, acquired simultaneously. Note that Muc5b
staining in the WT control mouse appears sparse
with use of the FITC conjugated secondary antibody
(scale bars, 10 μm). B, Muc5b distribution in mouse
lung. A more sensitive IHC staining technique using a
peroxidase conjugated secondary antibody revealed
a broad distribution of Muc5b in the airways. The
background image shows a tissue section taken
through the entire axial bronchus of a 90-day-old
wildtype C57BL/6J mouse. Note the dark staining of
the airway epithelium deep into the lung. Insets left
show that Muc5b is expressed in the axial bronchus
(a) and the proximal portion of minor daughter
branches (b), but it is absent in the terminal
bronchioles (c). a′, demonstration of immunolabel
specificity, with normal rabbit serum used in place of
anti-Muc5b. The image shown in a′ is taken from the
same portion of the axial bronchus in a neighbouring
section as shown in a. Scales bars, 250 μm (low
magnification) and 25 μm (high magnification).
of Clara cells apparently causes the ciliated cells to spread
out, reducing their overall height.
Munc13-2 involvement in other epithelial secretory
processes
Given the wide distribution of Munc13-2 in secretory cells,
it would be surprising were mucins the only secretory
Figure 7. Naphthalene injury selectively ablates
mucin-expressing cells
WT mice sensitized with OVA (controls), and
Munc13-2-deficient non-OVA-treated mice were
subjected to naphthalene injury, and the airways
examined 2 days later for AB/PAS+ staining. Images
shown are representative of 3 mice for each condition.
Scale bars, 15 μm.
cargo affected in the airways of the null animals. It can be
appreciated from Fig. 6A, for instance, that CCSP staining
appears more intense in the Munc13-2-deficient Clara
cells, relative to the WT control. To test whether CCSP
secretion might be also affected in the Munc13-2-deficient
animals, we used qRT-PCR and Western blotting
to determine the relative CCSP mRNA and protein
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expression levels in lung extracts, and repeated the
CCSP IHC without Muc5b co-staining. Figure 8 shows
clearly that CCSP mRNA levels are not affected in the
Munc13-2-deficient mice, whereas CCSP protein and
immunostaining in the Munc13-2-deficient Clara cells
was substantially increased, relative to their WT controls.
Figure 8. CCSP lipoprotein secretion is affected in
Munc13-2-deficient mice
CCSP mRNA (A; NS, n = 4) and protein (B; n = 3) levels in whole lung
extracts were assessed by qRT-PCR and Western blotting, respectively,
in non-OVA-sensitized WT and Munc13-2-deficient mice. A sample
blot is shown above the graph in B; ∗P < 0.05, Student’s t test. C,
bronchial epithelium was assessed for CCSP immunostaining in the
tracheas of the same mice. Images shown are representative. Scale
bars, 10 μm.
Hence, there also appears to be a CCSP secretory defect in
the Munc13-2-deficient mice.
To test whether epithelial secretory tissues other than
the airways were affected in the Munc13-2 deficient
mice, a series of mucosal organs were sectioned and
stained with AB/PAS. Figure 9 shows that AB/PAS+
staining was increased in every tissue examined in the
Munc13-2-deficient animals, including nasal septum,
salivary gland, stomach, and small and large intestine,
dramatically so in some cases. Hence, the apparent
Figure 9. Mucin secretory defects in Munc13-2-deficient mice
are widespread
Tissues of several mucin-secreting organs in WT Munc13-2-deficient
mice, as indicated, were examined for AB/PAS+ staining. Images
shown are representative of 2–3 mice each. For salivary gland: SL,
sublingual; SM, submandibular. Nasal septum, scale bars, 10 μm;
other scale bars, 50 μm.
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defect in baseline secretion observed for the airways of
Munc13-2-deficient mice appears to be a widespread
abnormality.
Discussion
Munc13 function in the airway epithelium
The archetypal gene encoding exocytic priming protein,
Unc-13, was identified in a classic 1975 mutagenic study
of C. elegans as producing an severe uncoordinated
phenotype, i.e. they were paralysed (Brenner, 1974).
A functional problem in neurotransmitter release was
suggested in 1991 when the neurons in these worms
were discovered to have elevated levels of acethylcholine
(Hosono & Kamiya, 1991), which was confirmed in 1999
(Richmond et al. 1999; Augustin et al. 1999b). Cloning
and sequencing of the gene revealed that the only regions
of Unc-13 with homology to other proteins were its C1
and C2 domains (Maruyama & Brenner, 1991), structural
elements subsequently found preserved in its mammalian
homolog, Munc13 (Brose et al. 1995). While Munc13-1,
-2 and -3 have been studied extensively in the nervous and
endocrine system (for review, Brose & Rosenmund, 2002;
Martin, 2002), there have been very few studies in other
secretory cells. Munc13-4 has received substantial recent
attention for its function in the immune system, having
had several genetic diseases ascribed to its dysfunction (for
review, Fukuda, 2005; Hong, 2005), but few of these studies
relate to its molecular physiology.
In hippocampal neurons, all synaptic activity ceases in
mice lacking both normally expressed isoforms, Munc13-1
and ubMunc13-2, and nearly full function is restored
when either isoform is delivered exogenously to rescue
the primary defect (Rosenmund et al. 2002). The priming
activities of Munc13, per se, have been associated with
the C-terminal half of the molecule, in particular the
MUN domain (= MHD1 + MHD2) (Koch et al. 2000;
Basu et al. 2005; Stevens et al. 2005), which is consistent
with the high sequence similarity in its structure for all
the isoforms, including Munc13-4. Although less well
conserved and not essential for priming, the half of the
molecule lying upstream of the MUN domain appears
to be involved in Munc13 localization and recruitment.
The C1 domain, for instance, is essential for survival
in mice, because it mediates activation by DAG (Rhee
et al. 2002), and the C2A domain is essential for the
recruitment of Munc13-1 and ubMunc13-2 to the synaptic
active zone by RIM1a (Andrews-Zwilling et al. 2006).
Munc13-4 lacks both C1 and C2A domains, yet it is a Rab27
effector (Neeft et al. 2005; Fukuda, 2005) through inter-
actions with an unidentified structural element. Given the
importance of Munc13 in neurotransmitter and hormone
release, the N-terminal structural differences between the
airway-expressed ubMunc13-2 and Munc13-4 isoforms,
the strong dependence of airway mucin secretion on
PLC-coupled P2Y2-R signalling (von Kugelgen, 2006;
Davis, 1997; Kim et al. 2003), and the PKC-independent,
mucin secretory effects of PMA in airways (Abdullah
et al. 1997, 2003; Rossi et al. 2004), we predicted that
regulated mucin secretion would suffer severe disruption
in the Munc13-2-deficient mouse. Hence, finding that
Munc13-2, in fact, is not essential for agonist-induced
mucin secretion in metaplastic goblet cells was a major
surprise (Figs 2 and 3). Parsimony suggests that Munc13-4
is active in agonist-induced secretion and substitutes for
Munc13-2 in the null animals; however, the participation
of other, unidentified proteins in the granule priming
process cannot be ruled out.
Although not essential for regulated mucin secretion,
Munc13-2 deficiency did have two major consequences
in the airway epithelium which may provide clues to
its function. First, Clara cells in the Munc13-deficient
mice were observed to accumulate mucins under control
conditions (Figs 2, 5 and 6). The accumulation of mucins
did not appear to result from airway inflammation
in the Munc13-2-deficient mice, as there was no
increase in inflammatory cell numbers in the epithelium
or airway lumen, mucin gene expression was not
increased, and the mucin synthetic machinery was not
up-regulated (Fig. 4). The accumulation of secretory cargo
in Munc13-2-deficient mice (Figs 2, 3, 5 and 6) strongly
suggests that this isoform regulates baseline exocytic
release in these cells. Since there is almost no AB/PAS
staining in the WT mouse airways (Fig. 2A) under control
conditions, we predict that these mucins are secreted
immediately following synthesis, i.e. the stored pool of
mucin secretory granules is minimal. Interestingly, this
aberrant accumulation affected other secreted proteins
and organs other than the airways epithelium: CCSP
was also observed to accumulate in Clara cells, in the
absence of an up-regulation of its mRNA (Fig. 7), and
mucin secretion appeared to be affected in many mucosal
organs – in every tissue examined, the mucin-containing
cells were engorged in the Munc13-2-deficient animals
(Fig. 9). Hence, Munc13-2 control of a regulated, base-
line exocytic process may be a general secretory cell
phenomenon outside the nervous system, and may require
a general rethinking of ‘regulated’ versus ‘constitutive’
exocytic secretion.
Retention of significant mucin stores following
exposure to maximal agonist concentrations was the
second consequence of Munc13-2 deficiency; in contrast,
mucins were secreted fully from agonist-exposed
airways of OVA-treated WT mice (Figs 2 and 3). This
observation suggests either that Munc13-2 is substituted
incompletely by Munc13-4, or that a population of mucin
granules requires Munc13-2 uniquely for exocytic release.
One simple possibility requiring attention is that mucin
granules are ‘tagged’ with either or both Rab3d (Evans
et al. 2004) and Rab27a (Tolmachova et al. 2004), such that
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they are primed, accordingly, by Munc13-2 or Munc13-4.
Deciphering such scenarios, however, will require more
cellular level approaches than used in the present study.
Mucins in the mouse airway
Another unanticipated finding of this study on
Munc13-2-deficient mice was the accumulation of mucins
in Clara cells which serendipitously revealed these cells
to be the source of oligomeric mucins in the mouse
lung and thereby solved an ancient riddle. Work with
allergen-sensitized mice relevant to asthma, has identified
important inflammatory mediators underlying allergic
mucous metaplasia (e.g. see Cressman et al. 1998; Hershey,
2003; Elias, 2004), but in the great majority of these
studies Clara cells were considered to have transformed
to ‘goblet cells’. Recent work, however, has shown clearly
that these metaplastic ‘goblet cells’ are, in fact, still Clara
cells that continue to contain CCSP, but additionally
have accumulated mucins (Evans et al. 2004). This work
and a recent extension (Young et al. 2007), have shown
that Muc5ac and Muc5b mRNAs are, in fact, produced
in control mouse airways, with Muc5b dominating by
> 40-fold. Both Muc5ac and Muc5b gene expression is
up-regulated during allergic mucous metaplasia, Muc5ac
dramatically so. Hence, the Clara cell was most probably
the cell synthesizing mucins under control conditions, but
there was no direct evidence supporting this point of view.
The appearance of AB/PAS staining and the
accumulation of Muc5b in Munc13-2-deficient Clara cells
under non-inflammatory, non-metaplastic conditions in
which neither Muc5ac nor Muc5b mRNAs have changed
from control (Figs 2–6) offers the first direct evidence
that Clara cells synthesize and secrete oligomeric mucins.
The agarose immunoblots probed with a Muc5b-specific
antibody show that the mucins under non-reducing
conditions are present as an ordered array of oligomers
(Fig. 5), as they appear in other mucin-secreting cells
(Sheehan et al. 2004). Significantly, our Muc5b antibody
also detected mucins in WT control mice, both by agarose
immunoblotting (Fig. 5) and in Clara cells by IHC
(Fig. 6).
Muc5b
The findings that Muc5b is not only expressed in WT
mouse airways, but is the dominant oligomeric mucin
mRNA (Evans et al. 2004; Young et al. 2007; and Fig. 4)
and is detectible at the glycoprotein level (Figs 5 and 6)
was a surprising finding given that Muc5b is thought
to be the major mucin expressed in human large air-
ways submucosal glands, but not in superficial epithelium
(see Voynow et al. 2006). In the current studies, Muc5b
expression in mouse lungs at baseline localized to the
same anatomical sites (i.e. proximal airway Clara cells)
as seen when mucous metaplasia is induced in mouse
lungs following antigen challenge (Evans et al. 2004).
This finding supports the concept that multiple, distinct
subtypes of CCSP-expressing cells are present in mouse
lungs, based upon their tissue localization and progenitor
cell origins (Rawlins et al. 2007) and their phenotypic
responses to inflammation and injury (Reader et al. 2003;
Evans et al. 2004; Homer et al. 2006). The potential
significance of these findings is twofold.
First, human bronchioles, small airways < 2 mm
diameter, are similar in many respects to mouse air-
ways, including trachea (∼1 mm diameter). Like the
mouse airways, most non-ciliated secretory cells in
the human bronchiole lack AB/PAS+ staining (e.g. see
Jeffery et al. 1992), goblet cells comprise < 1% of the
epithelium (Thurlbeck, 1990), and inflammation leads
to mucous metaplasia (Thurlbeck, 1990; Hogg, 2004).
Given these similarities, our results suggest that MUC5B
is probably also expressed in human bronchiolar secretory
cells, the ‘Clara cells’ of some investigators (e.g. Boers
et al. 1999). Existing evidence from in situ hybridization
shows MUC5B gene expression in human bronchiolar
epithelium (see Fig. 4 in Reid et al. 1997); however,
a cautious interpretation of the result is required by
distinctly goblet cell-like distribution of label and the
source of tissue, pathology specimens removed during
surgeries.
Second, should MUC5B prove to be secreted from
human bronchiolar secretory cells, then we speculate
that in the normal human lung this mucin functions as
the primary mucin in mucociliary clearance: it would
transit onto bronchial surfaces from both the small air-
ways, as well as, more proximally, from submucosal
glands. If MUC5B/Muc5b indeed functions primarily in
mucociliary clearance, then MUC5AC/Muc5ac may sub-
serve some other defensive function in the airways, e.g.
cough clearance.
In summary, the Munc13-2-deficient mouse has
revealed unexpectedly that this priming protein is not
essential for agonist-regulated mucin secretion, but it does
appear to regulate a tonically active, baseline secretory
pathway in the airways and other mucosal tissues. In the
absence of Munc13-2, oligomeric mucins accumulate in
airway Clara cells, and, surprisingly, Muc5b proves to
comprise a major fraction of the mucins in gene-deficient
mice. Muc5b glycoprotein is also expressed in WT Clara
cells, though in amounts too small to be visualized with
AB/PAS staining.
References
Abdullah LH, Bundy JT, Ehre C & Davis CW (2003). Mucin
secretion and PKC isoforms in SPOC1 goblet cells:
differential activation by purinergic agonist and PMA.
Am J Physiol Lung Cell Mol Physiol 285, L149–L160.
C© 2008 The Authors. Journal compilation C© 2008 The Physiological Society
1990 Y. Zhu and others J Physiol 586.7
Abdullah LH, Conway JD, Cohn JA & Davis CW (1997).
Protein kinase C and Ca2+ activation of mucin secretion in
airway goblet cells. Am J Physiol Lung Cell Mol Physiol 273,
L201–L210.
Abdullah LH, Davis SW, Burch L, Yamauchi M, Randell SH,
Nettesheim P & Davis CW (1996). P2u purinoceptor
regulation of mucin secretion in SPOC1 cells, a goblet cell
line from the airways. Biochem J 316, 943–951.
Andrews-Zwilling YS, Kawabe H, Reim K, Varoqueaux F &
Brose N (2006). Binding to RAB3A-interacting molecule
RIM regulates the presynaptic recruitment of Munc13–1 and
ubMunc13–2. J Biol Chem 281, 19720–19731.
Arvan P & Castle D (1998). Sorting and storage during
secretory granule biogenesis: looking backward and looking
forward. Biochem J 332, 593–610.
Augustin I, Betz A, Herrmann C, Jo T & Brose N (1999a).
Differential expression of two novel Munc13 proteins in rat
brain. Biochem J 337, 363–371.
Augustin I, Rosenmund C, Sudhof TC & Brose N (1999b).
Munc13-1 is essential for fusion competence of
glutamatergic synaptic vesicles. Nature 400, 457–461.
Bai J & Chapman ER (2004). The C2 domains of synaptotagmin
– partners in exocytosis. Trends Biochem Sci 29, 143–151.
Basu J, Shen N, Dulubova I, Lu J, Guan R, Guryev O, Grishin
NV, Rosenmund C & Rizo J (2005). A minimal domain
responsible for Munc13 activity. Nat Struct Mol Biol 12,
1017–1018.
Betz A, Thakur P, Junge HJ, Ashery U, Rhee JS, Scheuss V,
Rosenmund C, Rettig J & Brose N (2001). Functional
interaction of the active zone proteins Munc13-1 and RIM1
in synaptic vesicle priming. Neuron 30, 183–196.
Boers JE, Ambergen AW & Thunnissen FB (1999). Number and
proliferation of Clara cells in normal human airway
epithelium. Am J Respir Crit Care Med 159, 1585–1591.
Bossi G & Griffiths GM (2005). CTL secretory lysosomes:
biogenesis and secretion of a harmful organelle. Semin
Immunol 17, 87–94.
Brenner S (1974). The genetics of Caenorhabditis elegans.
Genetics 77, 71–94.
Brose N, Hofmann K, Hata Y & Sudhof TC (1995). Mammalian
homologues of Caenorhabditis elegans unc-13 gene define
novel family of C2-domain proteins. J Biol Chem 270,
25273–25280.
Brose N & Rosenmund C (2002). Move over protein kinase C,
you’ve got company: alternative cellular effectors of
diacylglycerol and phorbol esters. J Cell Sci 115,
4399–4411.
Cho W & Stahelin RV (2006). Membrane binding and
subcellular targeting of C2 domains. Biochim Biophys Acta
1761, 838–849.
Cohn L, Whittaker L, Niu N & Homer RJ (2002). Cytokine
regulation of mucus production in a model of allergic
asthma. Novartis Found Symp 248, 201–213.
Colon-Gonzalez F & Kazanietz MG (2006). C1 domains
exposed: from diacylglycerol binding to protein–protein
interactions. Biochim Biophys Acta 1761, 827–837.
Cressman VL, Hicks EM, Funkhouser WK, Backlund DC &
Koller BH (1998). The relationship of chronic mucin
secretion to airway disease in normal and CFTR-deficient
mice. Am J Respir Cell Mol Biol 19, 853–866.
Davis CW (1997). Goblet cells: physiology and pharmacology.
In Airway Mucus: Basic Mechanisms and Clinical Perspectives,
ed. Rogers DF & Lethem MI, pp. 150–177. Berkhauser, Basel.
Davis CW & Abdullah LH (1997). In vitro models for airways
mucin secretion. Pulm Pharmacol Ther 10, 145–155.
Davis CW & Dickey BF (2008). Regulated airway goblet cell
mucin secretion. Annu Rev Physiol 70 (in press).
Dulubova I, Lou X, Lu J, Huryeva I, Alam A, Schneggenburger
R, Sudhof TC & Rizo J (2005). A Munc13/RIM/Rab3
tripartite complex: from priming to plasticity? EMBO J 24,
2839–2850.
Ehre C, Rossi AH, Abdullah LH, De Pestel K, Hill S, Olsen JC &
Davis CW (2005). Barrier role of actin filaments in regulated
mucin secretion from airway goblet cells. Am J Physiol Cell
Physiol 288, C46–C56.
Ehre C, Zhu Y, Abdullah LH, Olsen J, Nakayama KI, Nakayama
K, Messing RO & Davis CW (2007). nPKCε, a P2Y2-R
downstream effector in regulated mucin secretion from
airway goblet cells. Am J Physiol Cell Physiol 293,
C1445–C1454.
Elias J (2004). The relationship between asthma and COPD.
Lessons from transgenic mice. Chest 126, 111S–116S.
Evans CM, Williams OW, Tuvim MJ, Nigam R, Mixides GP,
Blackburn MR, DeMayo FJ, Burns AR, Smith C, Reynolds
SD, Stripp BR & Dickey BF (2004). Mucin is produced by
Clara cells in the proximal airways of antigen-challenged
mice. Am J Respir Cell Mol Biol 31, 382–394.
Foster WM, Walters DM, Longphre M, Macri K & Miller LM
(2001). Methodology for the measurement of mucociliary
function in the mouse by scintigraphy. J Appl Physiol 90,
1111–1117.
Fukuda M (2005). Versatile role of Rab27 in membrane
trafficking: focus on the Rab27 effector families. J Biochem
137, 9–16.
Gerber SH & Sudhof TC (2002). Molecular determinants of
regulated exocytosis. Diabetes 51 (Suppl. 1), S3–S11.
Gorr SU, Venkatesh SG & Darling DS (2005). Parotid secretory
granules: crossroads of secretory pathways and protein
storage. J Dent Res 84, 500–509.
Groneberg DA, Eynott PR, Oates T, Lim S, Wu R, Carlstedt I,
Nicholson AG & Chung KF (2002). Expression of MUC5AC
and MUC5B mucins in normal and cystic fibrosis lung.
Respir Med 96, 81–86.
Grubb BR, Jones JH & Boucher RC (2004). Mucociliary
transport determined by in vivo microdialysis in the airways
of normal and CF mice. Am J Physiol Lung Cell Mol Physiol
286, L588–L595.
Hershey GK (2003). IL-13 receptors and signaling pathways: an
evolving web. J Allergy Clin Immunol 111, 677–690.
Hogg JC (2004). Pathophysiology of airflow limitation in
chronic obstructive pulmonary disease. Lancet 364, 709–721.
Holmen JM, Karlsson NG, Abdullah LH, Randell SH, Sheehan
JK, Hansson GC & Davis CW (2004). Mucins and their
O-Glycans from human bronchial epithelial cell cultures.
Am J Physiol Lung Cell Mol Physiol 287, L824–L834.
Homer RJ, Zhu Z, Cohn L, Lee CG, White WI, Chen S & Elias
JA (2006). Differential expression of chitinases identify
subsets of murine airway epithelial cells in allergic
inflammation. Am J Physiol Lung Cell Mol Physiol 291,
L502–L511.
C© 2008 The Authors. Journal compilation C© 2008 The Physiological Society
J Physiol 586.7 Muc5b secretion defect in Munc13-2−/− mouse airways 1991
Hong KU, Reynolds SD, Giangreco A, Hurley CM & Stripp BR
(2001). Clara cell secretory protein-expressing cells of the
airway neuroepithelial body microenvironment include a
label-retaining subset and are critical for epithelial renewal
after progenitor cell depletion. Am J Respir Cell Mol Biol 24,
671–681.
Hong W (2005). Cytotoxic T lymphocyte exocytosis: bring on
the SNAREs! Trends Cell Biol 15, 644–650.
Hosono R & Kamiya Y (1991). Additional genes which result in
an elevation of acetylcholine levels by mutations in
Caenorhabditis elegans. Neurosci Lett 128, 243–244.
Jeffery PK, Gaillard D & Moret S (1992). Human airway
secretory cells during development and in mature airway
epithelium. Eur Respir J 5, 93–104.
Kaartinen L, Nettesheim P, Adler KB & Randell SH (1993). Rat
tracheal epithelial cell differentiation in vitro. In Vitro Cell
Dev Biol Anim 29A, 481–492.
Kim KC, Hisatsune A, Kim dJ & Miyata T (2003).
Pharmacology of airway goblet cell mucin release.
J Pharmacol Sci 92, 301–307.
Kirkham S, Sheehan JK, Knight D, Richardson PS & Thornton
DJ (2002). Heterogeneity of airways mucus: variations in the
amounts and glycoforms of the major oligomeric mucins
MUC5AC and MUC5B. Biochem J 361, 537–546.
Klenchin VA & Martin TF (2000). Priming in exocytosis:
attaining fusion-competence after vesicle docking. Biochimie
82, 399–407.
Koch H, Hofmann K & Brose N (2000). Definition of
Munc13-homology-domains and characterization of a novel
ubiquitously expressed Munc13 isoform. Biochem J 349,
247–253.
Kurosawa H, Wang CG, Dandurand RJ, King M & Eidelman
DH (1995). Mucociliary function in the mouse measured in
explanted lung tissue. J Appl Physiol 79, 41–46.
Mall M, Grubb BR, Harkema JR, O’Neal WK & Boucher RC
(2004). Increased airway epithelial Na+ absorption produces
cystic fibrosis-like lung disease in mice. Nat Med 10, 487–493.
Martin TF (2002). Prime movers of synaptic vesicle exocytosis.
Neuron 34, 9–12.
Maruyama IN & Brenner S (1991). A phorbol ester/
diacylglycerol-binding protein encoded by the unc-13 gene
of Caenorhabditis elegans. Proc Natl Acad Sci U S A 88,
5729–5733.
Miller SG & Moore HP (1991). Reconstitution of constitutive
secretion using semi-intact cells: regulation by GTP but not
calcium. J Cell Biol 112, 39–54.
Neeft M, Wieffer M, de Jong AS, Negroiu G, Metz CH, van
Loon A, Griffith J, Krijgsveld J, Wulffraat N, Koch H, Heck
AJ, Brose N, van der Kleijmeer M & SP (2005). Munc13-4 is
an effector of rab27a and controls secretion of lysosomes in
hematopoietic cells. Mol Biol Cell 16, 731–741.
Pfaffl MW (2001). A new mathematical model for relative
quantification in real-time RT-PCR. Nucleic Acids Res 29,
e45.
Plopper CG, Suverkropp C, Morin D, Nishio S & Buckpitt A
(1992). Relationship of cytochrome P-450 activity to Clara
cell cytotoxicity. I. Histopathologic comparison of the
respiratory tract of mice, rats and hamsters after parenteral
administration of naphthalene. J Pharmacol Exp Ther 261,
353–363.
Ponnambalam S & Baldwin SA (2003). Constitutive protein
secretion from the trans-Golgi network to the plasma
membrane. Mol Membr Biol 20, 129–139.
Rawlins EL, Ostrowski LE, Randell SH & Hogan BL
(2007). Lung development and repair: contribution
of the ciliated lineage. Proc Natl Acad Sci U S A 104,
410–417.
Reader JR, Tepper JS, Schelegle ES, Aldrich MC, Putney LF,
Pfeiffer JW & Hyde DM (2003). Pathogenesis of mucous cell
metaplasia in a murine asthma model. Am J Pathol 162,
2069–2078.
Reid CJ, Gould S & Harris A (1997). Developmental expression
of mucin genes in the human respiratory tract. Am J Respir
Cell Mol Biol 17, 592–598.
Rhee JS, Betz A, Pyott S, Reim K, Varoqueaux F, Augustin I,
Hesse D, Sudhof TC, Takahashi M, Rosenmund C & Brose N
(2002). β Phorbol ester- and diacylglycerol-induced
augmentation of transmitter release is mediated by Munc13s
and not by PKCs. Cell 108, 121–133.
Richmond JE, Davis WS & Jorgensen EM (1999). UNC-13 is
required for synaptic vesicle fusion in C. elegans. Nat
Neurosci 2, 959–964.
Rose MC & Voynow JA (2006). Respiratory tract mucin genes
and mucin glycoproteins in health and disease. Physiol Rev
86, 245–278.
Rosenmund C, Sigler A, Augustin I, Reim K, Brose N &
Rhee JS (2002). Differential control of vesicle priming and
short-term plasticity by Munc13 isoforms. Neuron 33,
411–424.
Rossi AH, Salmon WC, Chua M & Davis CW (2007).
Calcium signaling in human airway goblet cells following
purinergic activation. Am J Physiol Lung Cell Mol Physiol
292, L92–L98.
Rossi AH, Sears PR & Davis CW (2004). Ca2+ dependency of
‘Ca2+-independent’ exocytosis in SPOC1 airway goblet cells.
J Physiol 559, 555–565.
Sheehan JK, Boot-Handford RP, Chantler E, Carlstedt I &
Thornton DJ (1991). Evidence for shared epitopes within the
‘naked’ protein domains of human mucus glycoproteins. A
study performed by using polyclonal antibodies and electron
microscopy. Biochem J 274, 293–296.
Sheehan JK, Kirkham S, Howard M, Woodman P, Kutay S,
Brazeau C, Buckley J & Thornton DJ (2004). Identification
of molecular intermediates in the assembly pathway of the
MUC5AC mucin. J Biol Chem 279, 15698–15705.
Stevens DR, Wu ZX, Matti U, Junge HJ, Schirra C, Becherer U,
Wojcik SM, Brose N & Rettig J (2005). Identification of the
minimal protein domain required for priming activity of
Munc13-1. Curr Biol 15, 2243–2248.
Stripp BR, Reynolds SD, Plopper CG, Boe IM & Lund J (2000).
Pulmonary phenotype of CCSP/UG deficient mice: a
consequence of CCSP deficiency or altered Clara cell
function? Ann N Y Acad Sci 923, 202–209.
Sudhof TC (2004). The synaptic vesicle cycle. Annu Rev
Neurosci 27, 509–547.
Thornton DJ & Sheehan JK (2004). From mucins to mucus:
toward a more coherent understanding of this essential
barrier. Proc Am Thorac Soc 1, 54–61.
Thurlbeck WM (1990). Pathology of chronic airflow
obstruction. Chest 97, 6S–10S.
C© 2008 The Authors. Journal compilation C© 2008 The Physiological Society
1992 Y. Zhu and others J Physiol 586.7
Tolmachova T, Anders R, Stinchcombe J, Bossi G, Griffiths
GM, Huxley C & Seabra MC (2004). A general role for
Rab27a in secretory cells. Mol Biol Cell 15, 332–344.
Trifaro JM, Lejen T, Rose SD, Pene TD, Barkar ND & Seward
EP (2002). Pathways that control cortical F-actin dynamics
during secretion. Neurochem Res 27, 1371–1385.
Van Winkle LS, Buckpitt AR, Nishio SJ, Isaac JM & Plopper CG
(1995). Cellular response in naphthalene-induced Clara cell
injury and bronchiolar epithelial repair in mice. Am J Physiol
Lung Cell Mol Physiol 269, L800–L818.
Varoqueaux F, Sigler A, Rhee JS, Brose N, Enk C, Reim K &
Rosenmund C (2002). Total arrest of spontaneous and
evoked synaptic transmission but normal synaptogenesis in
the absence of Munc13-mediated vesicle priming. Proc Natl
Acad Sci U S A 99, 9037–9042.
von Kugelgen I (2006). Pharmacological profiles of cloned
mammalian P2Y-receptor subtypes. Pharmacol Ther 110,
415–432.
Voynow JA, Gendler SJ & Rose MC (2006). Regulation of
mucin genes in chronic inflammatory airway diseases.
Am J Respir Cell Mol Biol 34, 661–665.
Williams OW, Sharafkhaneh A, Kim V, Dickey BF & Evans CM
(2006). Airway mucus: From production to secretion.
Am J Respir Cell Mol Biol 34, 527–536.
Young HW, Williams OW, Chandra D, Bellinghausen LK,
Perez G, Suarez A, Tuvim MJ, Roy MG, Alexander SN,
Moghaddam SJ, Adachi R, Blackburn MR, Dickey BF &
Evans CM (2007). Central role of Muc5ac expression in
mucous metaplasia and its regulation by conserved
5′-elements. Am J Respir Cell Mol Biol 37, 273–290.
Zhang B & Ginsburg D (2003). Getting secretory granules
ready for prime time. Cell 115, 372–373.
Acknowledgements
The authors thanks Dr Nils Brose for the gift of the Munc13-2 null
mice, and Dr Michael Tuvim for assistance with quantification.
Research in the Davis laboratory was supported by grants from
the NHLBI (HL063756) and the North American Cystic Fibrosis
Foundation; research in the Evans and Dickey laboratories
was supported by grants from the NHLBI (HL072984; B.F.D.),
North American Cystic Fibrosis Foundation and American Lung
Association (RG-22720-N; C.E.), and the MD Anderson Cancer
Center (P30CA16672; B.F.D. and C.E.).
C© 2008 The Authors. Journal compilation C© 2008 The Physiological Society
